Kodiak Sciences Inc. is a precommercial, retina-focused biotechnology company headquartered in Palo Alto, California. The company develops treatments for major retinal vascular diseases using its proprietary Antibody Biopolymer Conjugate (ABC) platform, which is designed to extend how long therapies last inside the eye and reduce the frequency of injections.
Its lead candidate, Zenkuda (tarcocimab tedromer, formerly KSI-301), is an anti-VEGF therapy backed by five positive Phase 3 studies across wet age-related macular degeneration (wet AMD), diabetic retinopathy, and retinal vein occlusion. Kodiak is also advancing tabirafusp-ted (KSI-501), a bispecific IL-6/VEGF conjugate, and KSI-101, a bispecific targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI). Investors follow the stock closely because the company is approaching its first potential regulatory filing and commercial launch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, KOD rose from a closing price of $87.72 on October 21, 2026 to $97.17 on November 20, 2026, a gain of about 10.8%. The move was not linear: the stock climbed to a high near $111 in mid-November before pulling back modestly.
The quarterly picture is substantially stronger. Three months earlier, KOD closed at $39.84 on August 20, 2026. From that level to $97.17, the stock advanced roughly 144%, reflecting the market's re-rating of the company's late-stage pipeline after pivotal clinical data. The contrast between the two periods underscores that most of the stock's value creation occurred during a single catalyst-driven event in late September, with the last 30 days representing a more moderate consolidation of those gains. From what I see, this pattern highlights how clinical news can reshape valuations quickly.
The last 30 days were shaped by follow-through from the September DAYBREAK readout and a series of company-specific updates. Kodiak reported third-quarter 2026 financial results on November 12, posting a net loss per share of $1.05 versus a consensus estimate of $1.01, and stating that its roughly $88.7 million in cash is expected to support operations into 2027.
Analyst activity also supported sentiment. UBS raised its price target on KOD to $150 from $120 while maintaining a Buy rating, and the broader analyst consensus stands at "Strong Buy" with an average 12-month target near $129.50. Additionally, Kodiak presented Phase 3 DAYBREAK data across its late-stage programs at the AAO 2026 annual meeting, reinforcing investor confidence in the pipeline ahead of the anticipated BLA filing. One thing that stands out here is how analyst upgrades can sustain momentum after a major catalyst.
The dominant driver of the quarterly move was the September 28, 2026 announcement that Zenkuda and tabirafusp-ted both met their primary endpoints in the Phase 3 DAYBREAK study in wet AMD, demonstrating non-inferior vision gains versus aflibercept. In the study, 54% of Zenkuda-treated patients reached a six-month dosing interval under strict treat-to-dryness criteria, a durability profile that differentiates it from standard-of-care anti-VEGF therapies such as Regeneron's EYLEA.
The market reacted forcefully, sending KOD shares up more than 150% in a single session. The results validated the ABC platform and positioned Zenkuda for a three-indication Biologics License Application planned for the fourth quarter of 2026. The broader narrative of a clinical-stage company nearing its first commercial opportunity drove the multi-month re-rating far more than any short-term trading dynamics.
Several milestones could shape KOD's trajectory in the months ahead. The most immediate is the planned fourth-quarter 2026 submission of a Biologics License Application for Zenkuda across wet AMD, diabetic retinopathy, and retinal vein occlusion, followed by KSI-101 PEAK 1 topline data expected in December. Investors will also monitor the tabirafusp-ted ALTO Phase 3 program in diabetic macular edema and further regulatory updates.
Key risks include Kodiak's precommercial status and negative cash flow, which may require additional capital raises, as well as the inherent uncertainty of regulatory review and commercial execution in a competitive ophthalmology market. Macroeconomic conditions and biotech sector sentiment may also influence near-term trading, though clinical and regulatory catalysts are expected to remain the primary drivers. I’m watching this closely as the regulatory timeline unfolds.
In my analysis of stocks like this, I often turn to Tickeron’s Trending AI Robots to see how automated strategies are positioning across the market. The page curates top-performing bots from a wide marketplace, helping highlight data-driven approaches that align with current conditions without replacing fundamental review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
KOD's Aroon Indicator triggered a bullish signal on November 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 217 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where KOD advanced for three days, in 231 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for KOD moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 36 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KOD as a result. In 57 of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for KOD turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KOD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
KOD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KOD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: KOD's P/B Ratio (102.150) is slightly higher than the industry average of (3.596). P/E Ratio (-23.699) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KOD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel therapies for the treatment of retinal disease
Industry Biotechnology